Key result
PBMV in severe MS with moderate MR yields similar 30-day major events versus less MR.
Why the study?
Does percutaneous balloon mitral valvotomy safely improve outcomes in patients with severe mitral stenosis and moderate mitral regurgitation?
Cohort (n=225)
Does percutaneous balloon mitral valvotomy safely improve outcomes in patients with severe mitral stenosis and moderate mitral regurgitation?
PBMV may be a safe and effective option for patients with severe mitral stenosis and moderate mitral regurgitation, providing sustained symptomatic benefit despite a higher risk of developing severe MR.
Answers are grounded in this paper and cite their sources.
May support PBMV consideration in moderate MR; leaves open randomized trials before practice change.
BACKGROUND: Percutaneous balloon mitral valvotomy (PBMV) is generally considered as a contraindication in patients with mitral stenosis (MS) associated with moderate to severe mitral regurgitation (MR). We sought to compare the safety and efficacy of PBMV in patients with severe MS and with moderate MR with those with less than moderate or no MR. MATERIALS AND METHODS: were screened into two groups: Group I with moderate MR and Group II with less than moderate or no MR. Clinical and echocardiographic assessments were done at 24h, 1 month, and 6 months post-procedure. A treadmill testing was done prior to PBMV and at 6 months. Primary safety outcome was a composite of cardiovascular death and development of severe MR with or without requirement for mitral valve replacement at 30 days of procedure. Efficacy of the procedure was measured as improvement in functional class, treadmill time, and mitral valve area (MVA) at 6 months. RESULTS: Seventeen patients with moderate MR and 208 patients with less than moderate MR underwent PBMV. Primary outcome showed no significant difference [2 (11.7%) in Group I vs. 8 (3.85%) in Group II, p=0.36]; occurrence of severe MR was higher in Group I [RR=4.87, 95% C.I.=1.42-16.69]. In Group I patients, improvement in treadmill time was seen in 12 (70.59%), functional class in 13 (76.47%), and MVA in all patients. CONCLUSION: In patients having severe MS associated with moderate MR, PBMV may be a safe option and provides sustained symptomatic benefit.
No takes yet. Share an insight, caveat, or question.
Vinayakumar et al. (2016) conducted a cohort in Severe mitral stenosis with moderate mitral regurgitation (n=225). Moderate mitral regurgitation vs. Less than moderate or no mitral regurgitation was evaluated on Composite of cardiovascular death and development of severe MR with or without requirement for mitral valve replacement at 30 days of procedure (p=0.36). PBMV in severe mitral stenosis with moderate MR yielded similar 30-day rates of cardiovascular death or severe MR compared to less MR.
Synapse has enriched 10 related papers. Consider them for comparative context: